TY - JOUR T1 - Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00138-2022 SP - 00138-2022 AU - Elisa Franceschi AU - Nora Drick AU - Jan Fuge AU - Tobias Welte AU - Hendrik Suhling Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/06/09/23120541.00138-2022.abstract N2 - As eosinophil granulocytes are the main effector cells in patients suffering from bronchial asthma [1], the introduction of anti-interleukin 5 (IL5) and IL5-receptor antibodies therapy led to a substantial change in severe asthma treatment [2, 3]. Despite a correlation between eosinophils and response to antibody therapy is known, only few data regarding biomarkers and predicting factors for treatment outcome are available [4]. As eosinophil blood levels are influenced by oral and inhaled steroid therapy, we assumed that the dosage of eosinophilic cationic protein (ECP) might be a better biomarker to predict therapy response.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interestCompeting interests: the authors declare that they have no competing interests ER -